Agilent Technologies, Inc. Q3 2026 Earnings Call Summary

1Key Financial Results and Metrics

Revenue: $1.88 billion, up 7.3% on a core basis, exceeding guidance by 140 basis points.

Operating Margin: 27.2% (excluding tariff refunds), 28.3% including $20 million in tariff refunds.

Earnings Per Share (EPS): $1.56 (excluding refunds), $1.62 including refunds, both above guidance.

Operating Cash Flow: $519 million; Free Cash Flow: $439 million (96% net income conversion).

Gross Margin: 56.4% (54.9% excluding tariff refunds), reflecting strong incremental volume leverage.

2Strategic Updates and Business Highlights

Growth Drivers: Key areas include pharma (12% growth), diagnostics, applied markets (chemicals and advanced materials), and strong performance in China (9% growth).

Ignite Operating System: Continued positive impact on operational efficiency and pricing strategy, contributing approximately 200 basis points to revenue growth.

Product Innovations: Successful launches, including the 9500 Triple Quad ICP-MS and the Altura column family, driving strong demand and customer satisfaction.

Sustainability Initiatives: Recognized as one of TIME's World's Most Sustainable Companies and upgraded to AAA by MSCI ESG.

3Forward Guidance and Outlook

Full-Year Revenue Guidance: Expected to be between $7.49 billion and $7.51 billion, reflecting 5.8% to 6% core growth.

EPS Guidance: Projected between $6.12 and $6.15 (excluding tariff refunds) and $6.18 to $6.21 including refunds, indicating robust growth of 10% at the midpoint.

Q4 Revenue Guidance: Anticipated between $1.98 billion and $2 billion, with continued growth momentum and contributions from Biocare.

4Bad News, Challenges, or Points of Concern

Diagnostics Growth: Grew at 6%, slightly below expectations, despite strong underlying orders; backlog issues noted.

Europe Performance: Low single-digit growth, attributed to tough year-over-year comparisons and geopolitical disruptions.

C&E Business: Facing macroeconomic pressures, particularly in the chemical and energy sectors, with expectations for continued volatility.

Inflationary Pressures: Ongoing cost pressures from geopolitical tensions and rising material costs, though mitigated by Ignite efficiencies.

5Notable Q&A Insights

Specialty CDMO Business: Strong growth of nearly 30% in Q3, with confidence in mid-teens growth over the long term; Train C expected to ramp up revenue generation in 2027.

Reshoring Dynamics: Agilent secured orders from five of the top ten global pharma companies, with expectations for incremental growth from reshoring initiatives.

China Market: Strong double-digit growth in pharma and food sectors; ongoing investments from biotech and large pharma companies noted as key drivers.

Pricing Strategy: Continued strong pricing momentum, exceeding initial targets, with expectations to maintain this into future quarters.

Future Opportunities: Potential growth in mRNA personalized cancer vaccines discussed, with a focus on long-term impacts rather than immediate results. Overall, Agilent Technologies reported a strong Q3 2026, with solid financial performance driven by strategic initiatives and market demand, while also facing some challenges in specific sectors and regions. The company remains optimistic about future growth, particularly in the context of ongoing innovations and market dynamics.